Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Bullboard Posts
Comment by jjwilsonon Sep 15, 2016 4:22pm
113 Views
Post# 25242252

RE:Can someone explain why ? :(

RE:Can someone explain why ? :(
Why hasn't the share price reacted to the recent successes?  I think it's the same reason as every other time - Promis is simply too small, has no analyst coverage and doesn't trade on a US exchange.  But the important thing is that share price doesn't really matter much.  Here's my thinking:  my expectation, and think most other shareholders expect the same thing, is that ultimately the payoff will come in the form of a buyout of some sort or the sale of the IP.  The value of that buyout or sale is not tied to the shareprice at the time of the sale.  If some BigPharma decides they want the IP the offer to buy will not be affected by the shareprice.  Although there is a feelgood aspect to seeing a rising shareprice ultimately it only matters if you are planning to flip for pennies or settle for a small profit. Now, I admit that shareprice does have some effect when you consider dilution from financings, opinion/sentiment of potential investors etc.  All those considerations will be quickly forgotten if/when a buyout occurs.
Bullboard Posts